References
- Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens- Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-24.
- Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8. https://doi.org/10.1212/01.WNL.0000156354.20227.F0
- Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-4. https://doi.org/10.1111/j.1365-2133.1996.tb06976.x
- Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl 7: S8-16. https://doi.org/10.1111/j.1528-1157.1998.tb01679.x
- Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-6. https://doi.org/10.1212/WNL.49.2.542
- Larsen A, Piepgras D, Chyatte D, Rizzolo D. Trigeminal neuralgia: diagnosis and medical and surgical management. JAAPA 2011; 24: 20-5.
- Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-36. https://doi.org/10.1016/S1081-1206(10)61112-X
- Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine-- the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71: 325-8. https://doi.org/10.4103/0378-6323.16782
- Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCARstudy. J Invest Dermatol 2008; 128: 35-44. https://doi.org/10.1038/sj.jid.5701033
- Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118: 233-41. https://doi.org/10.1016/j.jaci.2006.03.005
- Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85. https://doi.org/10.1056/NEJM199411103311906
- Huang LY, Liao WC, Chiou CC, Lou JP, Hu P, Ko FC. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepineinduced Stevens-Johnson syndrome. J Formos Med Assoc 2007; 106: 1032-7. https://doi.org/10.1016/S0929-6646(08)60079-0
- Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32. https://doi.org/10.1016/j.jaad.2007.08.036
Cited by
- Carbamazepine vol.1450, pp.1, 2013, https://doi.org/10.1007/s40278-013-2799-1
- Analysis of Drugs Causing Severe Cutaneous Adverse Reactions, Based on the Korean Database of Spontaneously Reported Adverse Drug Reactions vol.86, pp.6, 2014, https://doi.org/10.3904/kjm.2014.86.6.710